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Introduction
Heavy cannabis use has previously been associated with adverse effects on mental health 1,2 and physical health 3 but also has been found to protect against insulin resistance through an association with reduced body mass index. 4 While preclinical studies have revealed that cannabinoid receptors and their ligands play important roles in regulating bone density, bone turnover and bone cell activity 5, 6 the effects of cannabis use on bone health in humans are unknown.
We have previously reported that young adult mice with targeted inactivation of the type 1 cannabinoid receptor (Cnr1 -/-) have increased bone density due to a reduction in osteoclast activity 7 and that cannabinoid receptor agonists stimulate bone resorption and osteoclast activity in vitro. 8 However, with increasing age,
Cnr1
-/-mice show increased rates of bone loss due to defects in osteoblast differentiation and accumulation of adipocytes in the bone marrow. 9 Mice with deficiency of the type 2 cannabinoid receptor (Cnr2 -/-) also show enhanced bone loss with age due to reduced bone formation. 5, 10, 11 In keeping with this, type 2 cannabinoid receptor agonists stimulate osteoblast proliferation and promote bone nodule formation in vitro. 12, 13 The GPR55 receptor has also been reported to influence osteoclast differentiation in vitro and bone mass in vivo.
Specifically, male mice with inactivation of GPR55 have increase bone mass and increased bone resorption whereas the GPR55 antagonist cannabidiol inhibits osteoclast formation induced by the GPR55 agonist lipophosphatidylinosotol. 14 The complexity of the situation is emphasised by the fact that the effects of cannabinoid receptor deficiency in mouse models are age and gender dependent 10, 15 as well as being dependent on background strain of the mice. 16 The aim of this study was to determine if heavy cannabis use influences bone metabolism in humans. In order to achieve this aim we investigated the association between recreational use of cannabis and various markers of bone health in a cross-sectional study of 170 regular cannabis users and 114 controls recruited from a single inner city general practice in the United Kingdom.
Materials and methods

Study subjects
We approached individuals aged >18 who were attending a general practice surgery for routine appointments between November 2011 and March 2013. Individuals were invited to take part if they had a history of current or previous use of tobacco or cannabis. After providing written informed consent participants completed a questionnaire in which details were collected on demographics, smoking and alcohol intake, cannabis use, use of other illegal drugs, dietary calcium intake by food frequency questionnaire, fracture history, family history of hip fracture, participation in sports, whether the subjects were weight bearing for more than 4 hours a day and medical history. Participants were also invited to undergo bone densitometry and to provide a blood sample for biochemical analysis.
Ethics
The study was approved by NHS Lothian Research & Development (project number: 2011/W/RH/01) and South East Scotland Research Ethics Committee 01 (reference number: 11/SS/0029).
Bone mineral density measurements
Bone density was measured by dual-energy X-ray absorptiometry (DEXA) using a QDR 4500 densitometer (Hologic, Bedford, MA, USA). The coefficient of variation was 1.4%, 1.3% and 1.2% for femoral neck, lumbar spine and total hip, respectively. The bone mineral density measurements were expressed as g/cm 2 as well as gender specific Z-scores using the manufacturer's reference data.
Biochemical measurements
Serum creatinine was measured using standard techniques. Serum N-terminal propeptide of type 1 procollagen (P1NP) and C-terminal telopeptide of type 1 collagen (CTX) were measured using enzyme chemiluminescent immunoassays on a COBAS 600 analyser (Roche Products Ltd, Penzberg, Germany) with a CV of <4% for P1NP and <5% for CTX across the working range of the assay. Serum total 25-hydroxyvitamin D [25(OH)D] was measured using tandem mass spectrometry. For this assay, 25(OH)D2 and D3 were extracted from serum after zinc sulphate protein precipitation using Isolute solid phase C18 extraction cartridges.
Potential interfering substances were removed by initial elution by 50% methanol followed by elution of the vitamins using 10% tetrahydrofuran in acetonitrile. Dried extracts were reconstituted prior to injection into a High Performance Liquid Chromatography Tandem Mass Spectrometer (LC-MS/MS) (Platinum Ultima Waters UK) in multiple reaction mode. The assay has a limit of detection of 2.5 nmol/L for D3 and 2.5 nmol/L for D2 and a CV of <10% for both D3 and D2 across the working range. The assay was calibrated using NIST aligned calibration material and has achieved certification in the Vitamin D External Quality Assessment Scheme (DEQAS) scheme.
Sample size
The study was powered to provide 90% or greater power to detect a 0.4-0.5 Z-score units difference in bone mineral density between heavy cannabis users and controls, which we felt it would be a clinically significant difference. Based on this assumption between 80 and 130 participants were required in the heavy cannabis use and control groups. 
Statistical methods
. For both models the PROCESS macro implements a Bootstrap inference and outputs a 95% confidence interval. Other drug use was inserted in the model as a moderator rather than mediator since proposed mediators should not be categorical variables. 30 To compare the number of fractures between groups, the incidence rate ratio was calculated by counting the number of fractures that had occurred since the age of starting cannabis use (or the age of starting smoking for the controls) and the difference between groups was calculated by Revman 5.3 software. The significance level was set at p=0.05 with the Bonferroni correction applied for multiple comparisons.
Results
Participant characteristics
Relevant clinical and demographic details of the study population are shown in Table 1 in which cannabis users were divided into moderate and heavy subgroups. Moderate cannabis use was defined as taking cannabis on more than 5 and less than 5000 times and heavy cannabis use defined as taking cannabis on more than 5000 occasions as suggested by Gruber et al. 31 Participants with 5 or fewer exposures were classified as controls.
Heavy cannabis users were younger than controls and they reported taking other illegal drugs more frequently. Details of the illegal drugs taken other than cannabis in each group are shown in Table 2 . There was a predominance of males in the heavy cannabis user group and fewer of the females were postmenopausal as compared with the controls and moderate users. Dietary calcium intake was higher in heavy cannabis users than in controls but body mass index (BMI) was significantly lower. There was no difference between the groups in alcohol intake, the proportion of individuals with a family history of hip fracture or the proportion who reported taking part in sports regularly. However, the proportion of heavy cannabis users who reported standing for more than 4 hours a day was lower than the control group. Moderate cannabis users were younger than controls, and of the females, fewer were postmenopausal. Moderate cannabis users smoked fewer cigarettes and took more illegal drugs than controls but otherwise had similar characteristics to the controls.
Bone mineral density and biochemical markers
Associations between cannabis use and markers of bone health are summarised in Table 3 . Bone mineral density, expressed as the gender specific Z-score was significantly lower in heavy cannabis users when compared with controls at the lumbar spine, femoral neck and total hip. Serum concentrations of the cterminal telopeptide of type 1 collagen (CTX) and the amino terminal propeptide fragment of type I collagen (PINP) were significantly higher in heavy cannabis users as compared with controls. Conversely, heavy cannabis users had significantly lower total 25(OH)D than controls. There was no significant correlation between 25(OH)D levels and either CTX or PINP concentrations (data not shown)
Fractures were also more common in heavy cannabis users.
Multiple linear regression analysis
To evaluate the relative contribution of cannabis exposure to the reduction in bone mineral density as opposed to other variables we employed multiple linear regression analysis using bone mineral density at each skeletal site as the dependent variable, and age, gender, BMI, menopausal status (yes/no), serum 25(OH)D (nmol/L), serum PINP (g/L), serum CTX (g/L), tobacco smoking (pack years), alcohol (units/week), dietary calcium intake (mg/day), participation in sports (yes/no), weight bearing for >4 hours daily (yes/no), and use of other illegal drugs (yes/no) as explanatory variables. All these variables were previously shown to contribute to the variance of bone mineral density. [19] [20] [21] [22] [23] [24] [26] [27] [28] Heavy cannabis use was introduced as a final possible predictor in the model, since it was the main variable of interest. The results, summarised in Table 4 , showed that heavy cannabis use was an independent predictor of low bone mineral density at all three skeletal sites. Relative weight analysis 29 showed that the heavy cannabis use explained 5.4% (p=0.035), 3.9% (p=0.010) and 5.8%
(p=0.001) of the variance in bone mineral density at the lumbar spine, femoral neck and total hip, respectively.
Body mass index explained a large part the variance at the lumbar spine (38.7%, p=0.002), femoral neck (32.3%, p=0.001) and total hip (55.2%, p=0.001).
Mediation and moderation analyses
Mediation and moderation analyses were performed in order to examine the potential mechanisms by which heavy cannabis use affects bone mineral density at each skeletal site, taking other predictive factors into account. Mediation analysis provides an insight into whether the effects of a variable of interest on an endpoint of interest is mediated directly or indirectly and moderation analysis predicts whether the effects of this variable on the outcome of interest are influence by a moderator variable . 30 The results of the analysis are summarised in Table 4 and Figure 2 . For lumbar spine the mediation model included heavy cannabis intake, BMI and dietary calcium intake since these variables were found to be independent predictors of bone mineral density at this site by regression analysis. The model showed that the effects of heavy cannabis use on spine bone mineral density were indirect and mediated through BMI and paradoxically by dietary calcium intake which was increased in heavy cannabis users (Figure 2) . However, the  coefficient of BMI mediation (negative effect) was larger than the  coefficient of mediation through dietary calcium intake (positive effect) resulting in an overall negative effect on spine bone mineral density (Table 4) . Similar analyses for femoral neck and total hip bone mineral density included heavy cannabis use, age, gender, BMI and other illicit drug use which were found to be independent predictors of bone mineral density at these sites by regression analysis. BMI was considered as a possible mediator, other drug use was added as a moderator and age and gender were added as covariates. Mediation and moderation analyses showed that heavy cannabis use had a direct negative effect on femoral neck and total hip bone mineral density, with other drugs influencing this relationship. However, among those that did not take other drugs, the relationship between heavy cannabis use and total hip bone mineral density was also negative and statistically significant (Table 4) .
Discussion
Cannabinoid receptors and their ligands play key roles in several physiological and pathological processes.
1,32,33
The type 1 (CNR1) and type 2 (CNR2) cannabinoid receptors 5,9,12 as well as the orphan cannabinoid receptor GPR55 14 and their ligands have previously been reported to influence bone cell function, bone turnover and bone mass in mice with complex effects that are dependent on the ligand tested and the experimental system used. 5, 10 With this in mind, the aim of the present study was to investigate the effects of recreational cannabis use on bone health in humans, given that cannabis is one of the most widely used illegal drugs. The Cannabis sativa plant contains more than 100 cannabinoids but the most important are 9-tetrahydrocannabinol (THC) a partial agonist at the CNR1 and CNR2 receptors and cannabidiol (CBD) an antagonist at the GPR55 receptor. 32 Based on previous research, both of these cannabinoid receptor ligands might be expected to influence bone metabolism in man, 5 but it is difficult to predict what the overall effects on bone health might be given the fact that the effects of cannabinoid receptor ligands on the skeleton in preclinical studies are influenced by age, gender and genetic background.
The main findings to emerge from the present study were that heavy cannabis users had reduced bone density at all sites measured as compared with controls as well as a reduced body mass index, high bone turnover and an increased rate of fractures. The heavy cannabis user group also differed from the controls in age and gender distribution, serum 25(OH)D concentrations and dietary calcium intake as well as the proportion of time spent weight bearing each day. In view of the complexity of the situation we performed multiple regression analysis to determine if heavy cannabis use was an independent predictor of bone mineral density.
The regression analysis identified heavy cannabis use as an independent predictor of bone mineral density at all three skeletal sites with a relative contribution to the total amount of variance explained of 5.8% at the spine, 3.9% at the femoral neck and 5.4% at the total hip. Other significant predictors were body mass index and dietary calcium for spine bone mineral density; and age, gender, body mass index and use of other illegal drugs for hip bone mineral density.
In order to evaluate to what extent the effects of heavy cannabis use on bone density were direct or indirect we performed mediation analysis. This showed that while heavy cannabis use was an independent predictor of bone mineral density at the spine, the effects were indirect and mediated by reduced BMI but offset to an extent by high dietary calcium intake. At the femoral neck and total hip there was evidence of a direct effect heavy cannabis use on bone mineral density but that other illegal drug use was a moderator of the effect.
However, heavy cannabis use negatively influenced total hip bone mineral density even among those who did not use other illegal drugs.
The lower BMI that was observed in heavy cannabis users at first sight seems counterintuitive since agonists at the CNR1 receptor stimulate appetite. 34 However several investigators have found that cannabis users have
lower BMI values when compared with controls. 4, 35 The underlying mechanisms are unclear but it has been speculated that with long term use, THC might act as an antagonist at CNR1 and CNR2 receptors and reduce food intake through central and peripheral mechanisms. 35 So far as we are aware this is the first study of bone health in cannabis users. A notable strength is that we investigated a well characterised population of cannabis users who were matched with controls from the same geographical location. However the participants were derived from an inner city general practice in the UK and about two thirds of the heavy cannabis users had also taken other illicit drugs. While we cannot infer a cause and effect relationship between cannabis use and low bone mineral density because of the observational nature of the study, the participants underwent detailed phenotyping and we were able to correct for potential confounding factors through regression and mediation analysis which suggested that the association with low bone mineral density that we observed was due in part to the effects of cannabis. While further research will be required to investigate the mechanisms underlying the association we observed the findings reported here have important clinical implications in identifying heavy cannabis use as potential cause of low bone mineral density, increased bone turnover and predisposition to fractures. Values are number (%) or mean ± standard deviation, except incidence fracture rate ratio which is presented as the risk ratio with 95% confidence intervals. Differences between groups as assessed by GLM on bootstrapped values or Chi-square test. *p<0.05, **p<0.01, ***p<0.005 from controls. + Amongst alcohol users. The values shown are number of participants that reported use of the drug in question The standardised beta coefficient (), 95% confidence intervals (95% CI); and standard error (SE) are shown taking into account the independent predictors of bone density at each skeletal site, which were BMI and dietary calcium intake for the spine; and BMI, other illegal drug use, age and gender at the hip sites. Significant effects (whether direct or indirect) are indicated when the 95% confidence intervals do not cross zero. + Age and gender used as covariates. Models of used for PROCESS to theoretically assess mediation and moderation of the effects of heavy cannabis use on bone mineral density outcomes.
Figure 2. Results of mediation analysis
Mediation analysis showed that the effects of heavy cannabis use on spine bone mineral density were indirect and mediated by a reduced BMI whereas there was evidence for a direct effect on bone mineral density at the hip. See Table 4 and text for more details .
